MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2

MicroRNAs (miRNAs) regulate the proliferation and metastasis of cancer cells. Here, we showed that miR-152 was downregulated in non-small-cell lung cancer (NSCLC) tissues and cell lines. Overexpression of miR-152 suppressed cell proliferation and colony formation and also limited migration and invasion. Fibroblast growth factor 2 (FGF2) was confirmed as a direct target of miR-152. FGF2 knockdown suppressed cell proliferation, colony formation, migration and invasion, whereas FGF2 overexpression partially reversed the suppressive effect of miR-152. Furthermore, the presence of miR-152 was inversely correlated with FGF2 in NSCLC tissues. Overall, this study demonstrated that miR-152 suppressed the proliferation and invasion of NSCLC cells by downregulating FGF2. These findings provide novel insights with potential therapeutic applications for the treatment of NSCLC.

[1]  Bahauddeen M. Alrfaei,et al.  microRNA-100 Targets SMRT/NCOR2, Reduces Proliferation, and Improves Survival in Glioblastoma Animal Models , 2013, PloS one.

[2]  Lijun Xu,et al.  MicroRNA‐152 targets ADAM17 to suppress NSCLC progression , 2014, FEBS letters.

[3]  N. Lemoine,et al.  Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion , 2014, EMBO molecular medicine.

[4]  Jiachun Lu,et al.  MicroRNA-152 targets DNA methyltransferase 1 in NiS-transformed cells via a feedback mechanism. , 2013, Carcinogenesis.

[5]  Qing Xu,et al.  A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. , 2013, Journal of molecular cell biology.

[6]  Yue Wang,et al.  Down‐regulated microRNA‐152 induces aberrant DNA methylation in hepatitis B virus–related hepatocellular carcinoma by targeting DNA methyltransferase 1 , 2010, Hepatology.

[7]  R. Govindan,et al.  An emerging place for lung cancer genomics in 2013. , 2013, Journal of thoracic disease.

[8]  S. Zeinali,et al.  MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines , 2014, Cancer biology & therapy.

[9]  Wen-rong Gong,et al.  miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. , 2013, Oncology reports.

[10]  K. Vareli,et al.  Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value , 2010, Cancers.

[11]  R. Qin,et al.  miR-449a Regulates Proliferation and Chemosensitivity to Cisplatin by Targeting Cyclin D1 and BCL2 in SGC7901 Cells , 2014, Digestive Diseases and Sciences.

[12]  Lijun Xu,et al.  miR‐150 promotes the proliferation of lung cancer cells by targeting P53 , 2013, FEBS letters.

[13]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[14]  Paul Hofman,et al.  Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC , 2013, PloS one.

[15]  Yi Liu,et al.  MicroRNA-10b overexpression promotes non-small cell lung cancer cell proliferation and invasion , 2013, European Journal of Medical Research.

[16]  Zhen-ning Wang,et al.  The MicroRNA-148/152 Family: Multi-faceted Players , 2013, Molecular Cancer.

[17]  J. Xiong,et al.  Downregulation of miR‐16 promotes growth and motility by targeting HDGF in non‐small cell lung cancer cells , 2013, FEBS letters.

[18]  Wen-rong Gong,et al.  Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK , 2013, Molecular and Cellular Biochemistry.

[19]  X. Tu,et al.  MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. , 2013, Cancer letters.

[20]  Yi Huang,et al.  miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2 , 2013, Oncology letters.

[21]  Payam Shahi,et al.  microRNA-mediated regulation of the tumor microenvironment , 2013, Cell cycle.

[22]  Hermann Brenner,et al.  Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. , 2007, The Lancet. Oncology.

[23]  D. Tang,et al.  microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation , 2013, Medical Oncology.

[24]  M. Chopp,et al.  MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. , 2013, Cancer letters.

[25]  A. Casson,et al.  Basic Fibroblast Growth Factor (FGF-2) Overexpression Is a Risk Factor for Esophageal Cancer Recurrence and Reduced Survival, which Is Ameliorated by Coexpression of the FGF-2 Antisense Gene , 2005, Clinical Cancer Research.

[26]  H. Zhang,et al.  miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2 , 2014, Molecular and Cellular Biochemistry.

[27]  D. Rades,et al.  Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck , 2014, Strahlentherapie und Onkologie.

[28]  T. Mohr,et al.  Evidence for a role of FGF‐2 and FGF receptors in the proliferation of non‐small cell lung cancer cells , 1999, International journal of cancer.

[29]  L. Xue,et al.  miR-140 Suppresses Tumor Growth and Metastasis of Non-Small Cell Lung Cancer by Targeting Insulin-Like Growth Factor 1 Receptor , 2013, PloS one.

[30]  Leif E. Peterson,et al.  Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. , 2003, Cancer research.

[31]  Xiaozhi Wang,et al.  miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin , 2013, Human Cell.

[32]  R. Mahfouz,et al.  Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. , 2012, Critical reviews in oncology/hematology.

[33]  J. Zhou,et al.  MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine , 2014, Oncogene.

[34]  J. Inazawa,et al.  miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. , 2011, Cancer research.

[35]  P. Leung,et al.  Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells , 2013, PloS one.

[36]  P. Shao,et al.  miR‐152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines , 2013, The Prostate.

[37]  P. Mires.  Lines , 2006 .

[38]  J. Herbert,et al.  Tumor Vasculature Is Regulated by FGF/FGFR Signaling‐Mediated Angiogenesis and Bone Marrow‐Derived Cell Recruitment: This Mechanism Is Inhibited by SSR128129E, the First Allosteric Antagonist of FGFRs , 2015, Journal of cellular physiology.